Dr. Dolly Roy is a board-certified general neurologist and clinical specialist in treating Multiple Sclerosis. Growing up between the Midwest and California, she graduated summa cum laude with a major in Biochemistry and minor in Russian from Washington University in St. Louis where she was in the Scholars Program in Medicine. Dr. Roy continued in the Medical Scientist Training Program (MSTP) at Washington University School of Medicine earning her MD and PhD degrees and solidifying an interest in analytical and compassionate individualized medical care. She completed her Neurology residency at Stanford University School of Medicine where she developed her interests of trying to understand the intersection between coagulation and inflammation in mouse models for multiple sclerosis. She coauthored a Nature cover paper regarding this work in 2008, and later found an unexpected clinical correlation with elevated Factor VIII activity levels in patients experiecing poor recovery from multiple sclerosis relapses and increased clotting complications. She has presented novel preliminary work at the Americas Commiteefor Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting in 2018, at the International Society of Neuroimmunology (ISNI) meeting in 2018, at the American Academy of Neurology (AAN) meeting in 2019. Dr Roy is the co-Principal Investigator for her clinical trial trying to validate the importance of Factor VIII related blood tests as biomarkers for multiple sclerosis care that is set to launch in the Sacramento Area with Dignity Health/Common Spirit support. Prior to joining UCLA in 2017, Dr Roy practiced in Thousand Oaks and the San Fernando Valley for more than a decade and served as Stroke Director at Northridge Hospital for 7 years.
Medical Board Certification
- Identifying implications of accelerated thrombosis, inflammation and disease progression in neurological disease, especially in multiple sclerosis, with an aim to develop novel therapeutic and disease tracking options.
- Roy, DB, Shi, K, and FD Shi (2019) “Identifying Physiological Predictors of the Solumedrol Resistant Multiple Sclerosis Relapse and its Clinical Repercussions” presented at American Academy of Neurology AAN 71st Meeting 2019 in Philadelphia, PA May 7, 2019 as a poster presentation for MS Clinical Trials and Therapeutic Research.
- Roy, DB, Shi, K, and FD Shi (2018) “Identifying Physiological Predictors of the Solumedrol-Resistant Multiple Sclerosis Relapse and its Clinical Repercussions” presented orally at the International Society of Neuroimmunology Conference on August 30, 2018 in Brisbane, Australia
- Roy, DB, Shi, K, and FD Shi (2018) “Identifying a Role for Factor VIII Activity and vWF in Multiple Sclerosis and EAE Relapses” presented at ACTRIMS in San Diego, CA February 1, 2018 as a poster presentation for Biomarkers
- Roy, DB (2016) “Prolonged VZV IgM Serum Seropositivity in Multiple Sclerosis Is Associated with New Sensory Symptoms: A Case Series” presented at the Consortiums of Multiple Sclerosis Centers CMSC National Meeting at National Harbor, MD June 2, 2016 as a poster presentation for Epidemiology and Genetics.
- Roy, DB (2016) “Prolonged VZV IgM Serum Seropositivity in Multiple Sclerosis Is Associated with New Sensory Symptoms: A Case Series” International Journal of MS Care: 18, Supplement 1: 56
- Han, M.H.*, Hwang, S.*, Roy, D.B.*, Fernald, G., Raine, C., Robinson, W.H., Baranzini, S., Grinell, B., Sobel, R., Han, D. K., and Steinman, L. (2008) “Proteomic Analysis of Active Multiple Sclerosis Lesions Reveals Therapeutic Targets.” Nature 451: 1076-1081. * represents the first authors
- Prasad, D., Wright, K.J., Banerjee Roy, D., Bush, L.A., Cantwell, A.M., and Di Cera, E. (2002) “Redesigning the monovalent cation specificity of an enzyme.” Proc Natl Acad Sci. 100: 13785- 13790.
- Rose, T., LeMosy, E.K., Cantwell, A.M., Roy, D.B., Skeath, J.B., and Di Cera, E. (2002) “Three Dimensional Models of Proteases Involved in Patterning of the Drosophila Embryo.” JBC 278: 11320-11330.
- Roy, D.B., Rose, T., and Di Cera, E. (2001) “Replacement of Thrombin Residue G184 with Lys or Arg Fails to Mimic Na+ binding.” Proteins 43: 315-8.
- Di Cera, E., Vindigni, A., and Banerjee, D. (1997)"Energetic Dissection of Specificity in Serine Proteases.” in Thermodynamics and Structure Based Drug Design. Eds. J.E. Ladbury and P.R. Connelly. Springer-Verlag: 19-84.
Summa Cum Laude, Phi Beta Kappa, Mortar Board, Scholars Program in Medicine, Moog Scholar, American Neurological Association Resident research award winner, FASEB thrombosis award winner, American Heart Association grant recipient, ziMS grant recipient, Dignity Health/Common Spirit grant recipient, Multiple Sclerosis Society recognized physician